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1 Drug description 
Generic/Brand name/ATC code:  
Carfilzomib/Kyprolis
®
/L01XX45 
 
Developer/Company:  
Onyx Pharmaceuticals 
 
Description:  
Carfilzomib (Kyprolis
®
) is an epoxomicin derivate that selectively and irre-
versibly binds and predominantly inhibits the chymotrypsin-like activity of 
β5 and LMP7 subunits of the 20S component of proteasome, an enzyme re-
sponsible for degrading a large variety of cellular proteins. Due to proteasome-
mediated proteolysis inhibition, polyubiquinated proteins accumulate, which 
consecutively leads to cell-cycle arrest, induction of apoptosis and inhibition 
of tumour growth [1, 2]. 
Carfilzomib is administered intravenously (IV) over 2 to 10 minutes on two 
consecutive days each week for three weeks (on days 1, 2, 8, 9, 15 and 16), 
followed by a 12-day rest period (days 17 to 28); each 28-day period is consid-
ered one treatment cycle. During the first cycle, carfilzomib is administered 
at a dose of 20 mg/m
2
; if tolerated, the dose should be escalated to 27 mg/m
2
 in 
cycle two and should be maintained in subsequent cycles. The treatment can 
be continued until disease progression or unacceptable toxicity [3]. If signs 
of dose intolerance occur, either the dose can be reduced to 20 mg/m
2
 or the 
infusion time can be extended up to 30 minutes [4]. 
To reduce the risk of renal toxicity and of tumour lysis syndrome, patients 
who receive carfilzomib should be hydrated. Therefore, prior to each dose in 
cycle one, 250–500 ml of normal saline IV or another appropriate IV fluid 
should be given. If needed, an additional 250–500 ml of IV fluids can be ad-
ministered following carfilzomib administration and the hydration can be 
continued in subsequent cycles. Adequate fluid volume status should be main-
tained throughout the treatment; blood chemistries and fluid overload need 
to be monitored [3]. 
Premedication with dexamethasone is required to reduce the incidence and 
severity of infusion reactions, which are characterised by fever, chills, arthral-
gia, myalgia, facial flushing, facial oedema, vomiting, weakness, shortness of 
breath, hypotension, syncope, chest tightness or angina. Prior to all adminis-
tered doses of carfilzomib during cycle one and during the first cycle of dose 
escalation, dexamethasone should be given at a dosage of 4 mg (orally or IV). 
If infusion reactions develop or reappear during subsequent cycles, dexame-
thasone premedication (4 mg, orally or IV) should be administered again [3]. 
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2 Indication 
Carfilzomib (Kyprolis
®
) is indicated in patients with multiple myeloma who 
have received one to three prior therapies [3]. 
 
 
 
3 Current regulatory status 
In 2008, the European Commission granted orphan designation for carfilzo-
mib for the treatment of multiple myeloma [5]. On 18 December 2014, the 
EMA accepted the accelerated assessment request for carfilzomib (indicated 
for the treatment of adult patients with relapsed and refractory multiple my-
eloma who received at least two prior therapies that included bortezomib and 
an immunomodulatory agent, or for whom such treatments are not appropri-
ate) [6]. 
In July 2012, the FDA initially approved carfilzomib (Kyprolis
®
) under the 
provisions of accelerated approval regulations [7]. Carfilzomib was author-
ised for the treatment of patients with multiple myeloma who have received 
at least two prior therapies including bortezomib and an immunomodulato-
ry agent and have demonstrated disease progression on or within 60 days of 
completion of the last therapy [8]. 
On 24 July 2015, the label was revised. Carfilzomib is now indicated [3]  
 in combination with lenalidomide and dexamethasone for the treat-
ment of patients with relapsed multiple myeloma who have received 
one to three prior lines of therapy.  
 as a single agent for the treatment of patients with multiple myeloma 
who have received at least two prior therapies including bortezomib 
and an immunomodulatory agent and have demonstrated disease pro-
gression on or within 60 days of completion of the last therapy. Ap-
proval is based on response rate. Clinical benefit, such as improvement 
in survival or symptoms, has not been verified. 
Moreover, the FDA granted carfilzomib priority review with the Prescription 
Drug User Fee Act (target action date 26 July 2015) [9]. 
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4 Burden of disease 
Multiple myeloma is a haematological malignancy characterised by the neo-
plastic proliferation of plasma cells producing a monoclonal immunoglobulin.  
Common symptoms at presentation include anaemia, bone pain, elevated 
creatinine/serum protein, fatigue/generalised weakness, hypercalcaemia and 
weight loss; the majority of symptoms are related to the infiltration of plas-
ma cells (into the bone or other organs) or to kidney damage caused by ex-
cess light chains [10] (antibody subunits produced by neoplastic plasma cells). 
The incidence of multiple myeloma in Europe is 4.5–6.0/100,000 per year; 
mortality is 4.1/100,000 per year [11]. Multiple myeloma is most frequently 
diagnosed among people aged 65 to 74 years; the median age at diagnosis is 
69 years [2].  
According to the European Society for Medical Oncology (ESMO) the diag-
nosis of multiple myeloma should be based on the following tests [5]: 
 Detection and evaluation of the monoclonal component by serum and/ 
or urine protein electrophoresis; nephelometric quantification of im-
munoglobulin (Ig)G, IgA and IgM; characterisation of the heavy and 
light chains by immunofixation; serum-free light-chain measurement 
 Evaluation of bone marrow plasma cell infiltration: bone marrow as-
piration and/or biopsies are the standard options to evaluate the num-
ber and characteristics. The bone marrow should be used for cytoge-
netic/fluorescence in situ-hybridisation studies and also has the poten-
tial for immunophenotypic and molecular investigations 
 Evaluation of lytic bone lesions: a radiological skeletal bone survey 
(including spine, pelvis, skull, humeri and femurs) is necessary. A 
magnetic resonance imaging or computed tomography scan may be 
needed to evaluate symptomatic bony sites (even if the skeletal survey 
is negative and the patient has symptoms suggesting bone lesions). 
Moreover, magnetic resonance imaging provides greater detail and is 
recommended whenever spinal cord compression is suspected. Fluo-
rodeoxyglucose positron emission tomography is currently under eval-
uation but should not be used systematically 
 Complete blood cell count, including differential serum creatinine and 
calcium level. 
For the diagnosis of multiple myeloma the following criteria must be met [5]: 
 Clonal bone marrow plasma cells ≥ 10% or biopsy-proven  
plasmacytoma, and 
 evidence of end-organ damage that can be attributed to the underlying 
plasma-cell proliferative disorder (CRAB criteria): hypercalcaemia 
(serum calcium > 11.5 mg/dl), renal insufficiency (serum creatinine 
> 1.73 μmol/dl or estimated creatinine clearance < 40 ml/min) anae-
mia (normochromic, normocytic with a haemoglobin value of ≥ 2 g/dl 
below the lower limit of normal or a haemoglobin value < 10 g/dl) or 
bone lesions (lytic lesions, severe osteopenia or pathologic fractures). 
Relapsed myeloma should be defined as clinically active disease in patients 
who have received one or more prior therapies and with disease not refracto-
ry to the most recent treatment. Refractory multiple myeloma refers to pa-
tients who never achieve minor response or better, including “non-responding 
neoplastic 
proliferation of plasma 
cells 
median age at 
diagnosis: 69 years 
tests for the diagnosis  
of multiple myeloma 
diagnostic criteria 
definitions of 
relapsed/refractory 
multiple myeloma 
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but nonprogressing” patients (no significant change in M protein and no ev-
idence of clinical progression) and “primary refractory, progressive disease” 
[12]. Relapsed-and-refractory disease is defined as relapse of disease in pa-
tients who must have achieved minor response or better, patients either be-
come non-responsive while on salvage therapy or they progress within 60 days 
of last therapy. According to the International Myeloma Working Group, pro-
gressive disease is defined as an increase of > 25% from lowest response 
value in any one or more of the following [13]: 
 Serum M-component and/or (the absolute increase must be  
> 0.5 g/dL)  
 Urine M-component and/or (the absolute increase must be  
> 200 mg/24 h) 
 Only in patients without measurable serum and urine M-protein levels; 
the difference between involved and uninvolved serum free light chain 
(FLC) levels. The absolute increase must be > 10 mg/dL 
 Bone marrow plasma cell percentage; the absolute percentage must be 
> 10% 
 Definite development of new bone lesions or soft tissue plasmacytomas 
or definite increase in the size of existing bone lesions or soft tissue 
plasmacytomas 
 Development of hypercalcaemia (corrected serum calcium > 11.5 mg/dL 
or 2.65 mmol/L) that can be attributed solely to the plasma cell pro-
liferative disorder. 
There are two systems for the staging of multiple myeloma:  
 The Durie-Salmon system, which has traditionally been used, differ-
entiates 3 stages and, depending on kidney function/kidney damage, 
each stage is subclassified into A or B. This system is appropriate for 
assessing the extent of the disease or the size of the tumour [14] 
 The International Staging System (ISS), which is based on the measure-
ment of serum albumin and the levels of serum β2 microglobulin [15]:  
 Stage I: serum ß2-microglobulin < 3.5 mg/L, serum albumin  
≥ 3.5 g/dL 
 Stage II: not stage I or III (serum ß2-microglobulin < 3.5 mg/L 
but serum albumin < 3.5 g/dL, or serum ß
2
-microglobulin 3.5 to 
< 5.5 mg/L irrespective of the serum albumin level) 
 Stage III: serum ß2-microglobulin ≥ 5.5 mg/L. 
The Durie-Salmon system (developed in 1975) was widely adopted as the 
standard for multiple myeloma prognoses. In the 1980s, serum-ß
2
-microglobu-
lin was considered as the most powerful prognostic factor and reliable predic-
tor of survival duration. Over time, various other prognostic factors, including 
conventional cytogenetics emerged, whereby deletion of chromosome 13 is the 
most significant prognostic abnormality. Due to their statistical power and 
their wide availability, serum ß
2
-microglobulin and serum albumin were se-
lected from the various potential prognostic factors for the development of the 
ISS [15]. 
When patients are first diagnosed with multiple myeloma, stratification to high, 
intermediate or standard-risk disease is implemented, based on the results of 
fluorescence in situ hybridisation (FISH) for specific translocations and/or de-
letions, and conventional cytogenetics [16]. Generally, patients with a hypodip-
loid modal chromosome number including t(4;14)(p16;q32) or t(14;16)(q32;q23) 
are considered a high-risk group, hyperdiploid patients with (11;14)(q13;q32) 
staging/prognostic 
systems 
risk stratification 
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are considered a better prognostic group. When multiple myeloma progress-
es, it becomes more proliferative and a number of secondary chromosome ab-
errations develop [17]. According to the ISS, patients assigned to ISS stage 3 
(serum β2M ≥ 5.5 mg/l) have the poorest outcome [5]. 
In case of progressive disease, information on the initial response to therapy 
can be used to identify high-risk patients: patients who relapse less than 12 
months from first-line therapy or relapse on therapy are considered to be 
high-risk patients even if their previous risk evaluation yielded standard risk. 
Conversely, in patients who were previously considered to have high-risk dis-
ease and who relapse more than two years from initial therapy, the disease can 
be considered as standard-risk disease at the time of relapse in the absence 
of new additional high-risk cytogenetic abnormalities [3]. Retrospective stud-
ies, including a retrospective analysis of 102 patients with relapsed multiple 
myeloma [18], demonstrated inferior survival in patients who relapse less than 
12 months after initial therapy [3]. For patients who have high-risk disease 
at the time of relapse, participation in a clinical trial offers the best treatment. 
These patients may require more intensive treatment including prolonged 
maintenance therapy, multi-agent therapy, autologous stem-cell transplanta-
tion (ASCT) or consideration for allogeneic transplantation; particularly since 
these patients are not likely to respond to conventional therapies [3].  
In terms of differential diagnosis, benign causes presenting with similar man-
ifestations and other plasma cell dyscrasias need to be distinguished from 
multiple myeloma. The most common diseases to consider are monoclonal 
gammopathy of undetermined significance, smouldering multiple myeloma, 
Waldenström macroglobulinaemia, solitary plasmacytoma, primary amyloi-
dosis, POEMS (osteosclerotic myeloma: polyneuropathy, organomegaly, endo-
crinopathy, monoclonal protein, skin changes) syndrome and metastatic car-
cinoma [19]. 
 
 
 
5 Current treatment 
In patients with active myeloma, showing the CRAB criteria (hypercalcaemia 
> 11.0 mg/dl, creatinine > 2.0 mg/ml, anaemia: haemoglobin < 10 g/dl, ac-
tive bone lesions), and in patients who are symptomatic due to the underly-
ing disease, front-line treatment should be initiated.  
According to the ESMO Guidelines, for patients who are not eligible for au-
tologous stem cell transplantation (ASCT), an oral combination treatment 
with melphalan and prednisone plus novel agents (e.g. MPT: melphalan/pred-
nisone/thalidomide or VMP: bortezomib/melphalan/prednisone) is consid-
ered as standard of care. Another option is bendamustine plus prednisone 
for patients who have clinical neuropathy at time of diagnosis [11]. 
Transplant-eligible patients receive induction therapy (bortezomib combined 
with dexamethasone) followed by high-dose therapy with ASCT. However, da-
ta from phase II studies showed, that the addition of a third agent to borte-
zomib/dexamethasone, such as thalidomide, doxorubicin, lenalidomide or cy-
clophosphamide (VCD) resulted in higher response rates [5]. 
differential diagnosis 
front-line  
treatment 
Horizon Scanning in Oncology 
8 LBI-HTA | 2015 
The treatment aims of most patients with relapsed multiple myeloma are sim-
ilar to those at the time of initial diagnosis: achievement of disease control, 
amelioration of symptoms and improvement of quality of life [20]. However, 
despite the increased number of available treatment options, side effects of-
ten limit the choices of a significant number of patients. For patients with 
early relapse, the introduction of thalidomide, bortezomib and lenalidomide 
changed the poor prognosis and the poor response to conventional chemo-
therapy they were deemed to have [7]. 
For the treatment of relapsed and refractory disease, the ESMO states the 
following [5]: 
 in the relapse setting, the choice of therapy depends on several parame-
ters such as age, performance status, comorbidities, previous treatment 
(type, efficacy, tolerance), number of prior treatment lines, available 
remaining treatment options and the interval since the last therapy 
 lenalidomide has been approved by the EMA, in combination with dex-
amethasone and bortezomib either as single-agent or combined with 
pegylated doxorubicin 
 in the relapse setting, bortezomib is mostly used in combination with 
dexamethasone 
 thalidomide and bendamustine are frequently used and effective drugs, 
but not approved 
 data from phase II trials showed effectiveness of triplet combinations; 
however, only one randomised trial showed the superiority regarding 
PFS of bortezomib, thalidomide and dexamethasone over thalidomide 
plus dexamethasone in patients relapsing after ASCT 
 a second ASCT may be considered in young patients, providing that 
the patient responded well to the previous ASCT and had a PFS of 
more than 24 months 
 in patients with relapsed multiple myeloma, allogeneic SCT should 
only be carried out in the context of a clinical trial 
 if possible, patients should be offered to participate in clinical trials 
 pomalidomide and carfilzomib are both approved in the U.S. but not 
yet available in Europe outside clinical trials 
 other drugs or other classes of drugs (e.g. histone-deacetylase inhibitors 
or monoclonal antibodies are currently under development. 
 
 
  
achieving disease 
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6 Evidence 
A literature search was conducted on 18 May 2015 in four databases (Medline, 
Embase, CRD Database and The Cochrane Library). Search terms were “Car-
filzomib”, “Kyprolis”, “Multiple myeloma”, “Relapsed multiple myeloma” and 
“Refractory multiple myeloma”. The manufacturer was contacted but did not 
submit any further evidence. 
In total, 396 references were identified. Included in this report are: 
 1 phase III study, evaluating the efficacy and safety of carfilzomib with 
lenalidomide and dexamethasone compared with lenalidomide and dex-
amethasone in patients with relapsed multiple myeloma 
 6 phase II studies, described in chapter 6.2. 
Phase I studies, compassionate-use studies, case reports and case series of car-
filzomib were not included in this assessment. 
 
 
6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma [12, 21] 
Study  
identifier 
NCT01080391, EudraCT number: 2009-016839-35, Onyx-ID: ASPIRE trial (PX-171-009) 
Design Randomised, open-label, multicentre, phase III study 
Duration  Enrolment: 2010-07 to 2012-03 
Median follow-up: 32.3 months (carfilzomib with lenalidomide and 
dexamethasone), 31.5 months (lenalidomide and dexamethasone alone) 
Cut-off date for interim analyses: 2014-06-16 
Hypothesi
s 
 Superiority 
Funding Onyx Pharmaceuticals 
Treatment 
groups 
Intervention 
(n=392) 
Carfilzomib as a 10-minute infusion on days 1, 2, 8, 9, 15 and 16 (starting dose  
20 mg/m
2
 on days 1 and 2 of cycle 1, target dose 27 mg/m
2
 thereafter) during 
cycles 1 through 12 and on days 1, 2, 15 and 16 during cycles 13 through 18, 
after which carfilzomib was discontinued 
Lenalidomide (25 mg) was given on days 1 through 21 
Dexamethasone (40 mg) was administered on days 1, 8, 15 and 22 
Pre-treatment and post-treatment IV hydration (250 to 500 ml) was required 
during cycle 1 (and optional in subsequent cycles) 
Control 
(n=389) 
Lenalidomide (25 mg) was given on days 1 through 21 
Dexamethasone (40 mg) was administered on days 1, 8, 15 and 22 
Pre-treatment and post-treatment IV hydration (250 to 500 ml) was required 
during cycle 1 (and optional in subsequent cycles) 
Endpoints 
and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS Defined as the duration in months from randomisation to documented 
progressive disease or death due to any cause, whichever occurred 
earlier 
Overall survival OS Defined as the duration in months from the date of randomisation to the 
date of death due to any cause 
396 references were 
identified by 
systematic literature 
search in  
4 databases 
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Overall response 
rate 
OR
R 
Defined as the proportion of patients in each group who achieved 
stringent complete response (sCR), complete response (CR), very good 
partial response, or partial response as their best response assessed by 
International Myeloma Working Group (IMWG) criteria 
Endpoints 
and 
definitions 
(continuation) 
Duration of 
response 
DO
R 
For patients achieving partial response or better, defined as the duration 
in months from the start date of response to the earlier date of documented 
progressive disease or death due to any cause 
Health-related 
quality of life 
- Assessed with the use of the European Organisation for Research and 
Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire 
on day 1 of cycles 1, 3, 6, 12, 18 and approximately 30 days after the last 
treatment 
Safety - Data on adverse events were collected until 30 days after administration 
of the last dose of study treatment, and events were graded according to 
National Cancer Institute Common Terminology Criteria for Adverse 
Events, version 4.0 
Clinical benefit rate - Defined as the proportion of patients who achieved a best response of 
partial response or better according to International Myeloma Working 
Group Uniform Response Criteria or minimal response according to 
European Group for Blood and Marrow Transplant criteria 
Time to 
progression 
- Defined as the duration in months from the date of randomisation to the 
date of documented disease progression 
Time to next 
treatment 
- Defined as the duration in months from the date of randomisation to the 
date of initiating subsequent anti-myeloma therapy 
Results and analysis 
Analysis  
descriptio
n 
526 events (disease progression or death) were required to provide 90% power to detect a 25% reduction 
in the risk of disease progression or death (HR of 0.75) at a one-sided significance level of 0.025. An interim 
analysis was to be performed after approximately 420 events had occurred (80% of the planned total).  
An O’Brien-Fleming stopping boundary for efficacy was calculated with the use of a Lan-DeMets alpha 
spending function on the basis of the number of events observed at the data-cutoff date. All reported P 
values are two-sided. 
Safety analysis included all patients who received at least one dose of the study treatment. 
Analysis  
population 
Inclusion  Adults with relapsed multiple myeloma and measurable disease who had 
received 1–3 prior treatments 
 Patients previously treated with bortezomib were eligible provided that they did 
not have disease progression during treatment 
 Patients previously treated with lenalidomide and dexamethasone were eligible 
so long as they did not discontinue therapy because of adverse effects, have 
disease progression during the first 3 months of treatment, or have disease 
progression at any time during treatment if lenalidomide plus dexamethasone 
was their most recent treatment 
 All patients had adequate hepatic, haematologic and renal function (creatinine 
clearance ≥ 50 ml/minute) at screening 
Exclusion  Grade 3 or 4 peripheral neuropathy (or grade 2 with pain) within 14 days 
before randomisation 
 New York Heart Association class III or IV heart failure 
Characteristics  Intervention Control 
Age 
Median, years 
Range, years 
Distribution, % 
18–64 years 
≥ 65 years 
 
64.0 
38.0–87.0 
 
53.3 
46.7 
 
65.0 
31.0–91.0 
 
47.5 
52.5 
Male sex, % 54.3 58.6 
ECOG performance status, 
% 
0–1 
2 
 
89.9 
10.1 
 
91.2 
8.8 
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Cytogenetic risk at  
study entry, % 
High risk 
Standard risk 
Unknown 
 
 
12.1 
37.1 
50.8 
 
 
13.1 
42.9 
43.9 
Analysis  
population 
(continuation) 
Characteristics 
(continuation) 
Creatinine clearance 
Mean, ml/min 
Distribution, % 
30 to < 50 ml/min 
≥ 50 ml/min 
Unknown or other value 
 
85.0±28.9 
 
6.3 
93.4 
0.3 
 
85.9±30.2 
 
7.8 
90.4 
1.8 
Serum β2-microglobulin, % 
< 2.5 mg/litre 
≥ 2.5 mg/litre 
 
19.4 
80.6 
 
19.4 
80.6 
Previous regimens 
Median, number 
Range, number 
Distribution, % 
1 regimen 
2 or 3 regimens 
 
2.0 
1–3 
 
46.5 
53.3 
 
2.0 
1–3 
 
39.6 
60.1 
Previous therapies, % 
Bortezomib 
Lenalidomide 
 
65.9 
19.9 
 
65.7 
19.7 
Descriptiv
e 
statistics 
and 
estimated 
variability 
Treatment group Intervention Control 
Number of subjects 396 396 
PFS, months  
Median 
95% CI 
 
26.3  
23.3–30.5 
 
17.6  
15.0–20.6 
Median OS, months NE NE 
24-month OS rates (95% CI), % 73.3 (68.6–77.5) 65.0 (59.9–69.5) 
Number of deaths  (%) 143 (36.1) 162 (40.9) 
Best response, number (%)  
CR or better 
Stringent CR 
CR 
vgPR or better 
SD or PD 
 
126 (31.8) 
56 (14.1) 
70 (17.7) 
277 (69.9) 
14 (3.5) 
 
37 (9.3) 
17 (4.3) 
20 (5.1) 
160 (40.4) 
59 (14.9) 
ORR, % (95% CI) 87.1 (83.4–90.3) 66.7 (61.8–71.3) 
Clinical benefit rate, % (95% CI) 90.9 (87.6–93.6) 76.3 (71.8–80.4) 
Time to response, months 
Mean 
Median 
 
1.6±1.4 
1.0 
 
2.3±2.4 
1.0 
Duration of response, months 
Median 
95% CI 
 
28.6 
24.9–31.3 
 
21.2 
16.7–25.8 
QLQ-C30 Global Health Status and Quality of  
Life scale, least-squares mean estimates1 
Cycle 3, day 1 
Cycle 6, day 1 
Cycle 12, day 1 
Cycle 18, day 1 
 
 
60.44 
62.64 
62.32 
63.35 
 
 
57.23 
59.30 
56.75 
58.54 
                                                             
1
 minimal important difference (MID) for between-group differences on the QLQ-C30 Global Health Status/Quality 
of Life scale is 5 points, 2 and this MID was met at cycle 12 (5.56) and approached at cycle 18 (4.81) 
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Median time to progression, months 31.4 19.4 
Median time to next treatment, months 17.3 12.1 
Effect 
estimate 
per 
compariso
n 
Comparison groups Number of subjects (I vs. C) 396 vs. 396 
PFS HR 0.69 
95% CI 0.57–0.83 
P value 0.0001 
OS HR 0.79 
95% CI 0.63–0.99 
P value 0.04 
CR or  
better 
HR NR 
95% CI NR 
P value <0.001 
Very good partial response 
or better 
HR NR 
95% CI NR 
P value <0.001 
ORR HR NR 
95% CI NR 
P value <0.001 
Clinical benefit rate HR NR 
95% CI NR 
P value <0.001 
Median time to progression HR 0.62 
95% CI 0.50–0.76 
P value NR 
PFS subgroup analyses   
High/standard cytogenetic risk at study entry Number of subjects (I vs. C) 48/147 vs. 52/170 
HR 0.70/0.66 
95% CI 0.43 – 1.16/0.48 – 
0.90 
Previous/No previous treatment with bortezomib Number of subjects (I vs. C) 261/135 vs. 260/136 
HR 0.70/0.73 
95% CI 0.56-0.88/0.52-1.02 
Previous/No previous treatment with lenalidomide Number of subjects (I vs. C) 79/317 vs. 78/318 
HR 0.80/0.69 
95% CI 0.52-1.22/0.55-0.85 
Disease responsive/non-responsive to bortezomib 
in any previous regimen 
Number of subjects (I vs. C) 336/60 vs. 335/58 
HR 0.70/0.80 
95% CI 0.57-0.86/0.49-1.30 
Disease nonresponsive/responsive to bortezomib 
and refractory to immunomodulatory agent in any 
previous regimen 
Number of subjects (I vs. C) 24/27 vs. 372/369 
HR 0.89/0.70 
95% CI 0.45–1.77/0.57–0.85 
Disease refractory/not refractory to 
immunomodulatory agent in any previous regimen 
Number of subjects (I vs. C) 85/311 vs. 88/308 
HR 0.64/0.72 
95% CI 0.44-0.91/0.58-0.90 
Abbreviations: CI = confidence interval, CR = complete response, ECOG = Eastern Cooperative Oncology Group, HR = 
hazard ratio, NCT = National Clinical Trial, NE = not estimable, NR = not reported, OS = overall survival, PFS = pro-
gression-free survival, ORR = overall response rate, PD = progressive disease, PR = partial response, SD = stable disease, 
vgPR = very good partial response 
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Table 2: Adverse events (AEs) in the safety population
2
 
AE (according  
to NCI-CTC version 4.0) 
Intervention 
(N=392) 
Control 
(N=389) 
All grades  
N (%) 
Grade 3 or higher 
N (%) 
All grades 
N (%) 
Grade 3 or higher 
N (%) 
Most common non-haematologic AEs 
Diarrhoea 166 (42.3) 15 (3.8) 131 (33.7) 16 (4.1) 
Fatigue 129 (32.9) 30 (7.7) 119 (30.6) 25 (6.4) 
Cough 113 (28.8) 1 (0.3) 67 (17.2) 0  
Pyrexia 112 (28.6) 7 (1.8) 81 (20.8) 2 (0.5) 
Upper respiratory tract infection 112 (28.6) 7 (1.8) 75 (19.3) 4 (1.0) 
Hypokalaemia 108 (27.6) 37 (9.4)  52 (13.4) 19 (4.9) 
Muscle spasms 104 (26.5) 4 (1.0) 82 (21.1)  3 (0.8) 
Other AEs of interest 
Dyspnoea 76 (19.4) 11 (2.8) 58 (14.9) 7 (1.8) 
Hypertension 56 (14.3) 17 (4.3)  27 (6.9)  7 (1.8)  
Acute renal failure 33 (8.4) 13 (3.3)  28 (7.2)  12 (3.1)  
Cardiac failure 25 (6.4) 15 (3.8) 16 (4.1)  7 (1.8) 
Ischemic heart disease 23 (5.9)  13 (3.3)  18 (4.6) 8 (2.1) 
Abbreviations: AE = adverse event, N = number 
 
The ASPIRE trial [12, 21], a phase III study, evaluated the efficacy and safe-
ty of carfilzomib with lenalidomide and weekly dexamethasone (carfilzomib 
group) compared to lenalidomide and weekly dexamethasone alone (control 
group) in 792 patients with relapsed multiple myeloma for up to 18 cycles. 
The starting dose of carfilzomib was 20 mg/m
2
 on days 1 and 2 of cycle 1; the 
target dose was 27 mg/m
2
 thereafter. After cycle 18, carfilzomib was discon-
tinued. 
Patients with relapsed multiple myeloma and measurable disease who had 
1–3 prior treatments were eligible, as well as patients previously treated with 
bortezomib, provided that they did not have disease progression during treat-
ment. Furthermore, patients who received prior lenalidomide and dexametha-
sone were eligible if they did not discontinue therapy due to adverse effects, 
had disease progression during the first 3 months of treatment or had pro-
gression at any time during treatment (if lenalidomide plus dexamethasone 
was their most recent treatment). Patients with grade 3 or 4 peripheral neu-
ropathy (or grade 2 with pain) within 14 days before randomisation, or New 
York Heart Association were excluded. Median age was 64 years and the ma-
jority of the patients (90.5%) had an ECOG performance status of ≤ 1. Of all 
patients enrolled, less than 13% had a high cytogenetic risk, between 37% and 
43% had a standard risk at study entry and in 44% to 51% of patients the cy-
togenetic risk remained unknown.  
 
                                                             
2
 AEs reported in at least 25% of patients in either treatment group and other AEs of 
particular clinical relevance are listed, including all patients who received at least one 
dose of the study drug.  
comparing carfilzomib 
+ lenalidomide + 
dexamethasone  
with lenalidomide + 
dexamethasone alone 
median age of  
64 years 
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Patients in both groups had received a median of two previous regimens: 
bortezomib had been administered in 65.9% of patients in the carfilzomib 
group and in 65.7% of patients in the control group; 19.9% of patients in the 
carfilzomib group and 19.7% of patients the in control group had received 
prior lenalidomide therapy. 
At interim analysis with a median follow-up of 32.3 months in the carfilzo-
mib group and 31.5 months in the control group respectively, median PFS, 
the primary endpoint, was 26.3 months (95% CI 23.3–30.5) in the carfilzo-
mib group compared with 17.6 months (95% CI 15.0–20.6) in the control 
group (HR 0.69 for progression or death, 95% CI 0.57–0.83, p=0.0001). The 
PFS benefit was observed across all predefined subgroups. The median OS 
was not reached in either group, but there was a trend in favour of the carfil-
zomib group (HR for death 0.79, 95% CI 0.63–0.99). However, since these re-
sults are from the interim analysis, they have to be regarded with caution. The 
24-month OS rates were 73.3% (95% CI 68.6–77.5) in the carfilzomib group 
versus 65.0% (95% CI 59.9–69.5) in the control group.  
The ORR was 87.1% (95% CI 83.4–90.3) in the carfilzomib group compared 
to 66.7% (95% CI 61.8–71.3) in the control group (p<0.001); complete re-
sponse or better was achieved by 31.8% (carfilzomib group) and 9.3% (con-
trol group) of patients respectively (p<0.001). The mean time to a response 
was 1.6 months in carfilzomib group patients versus 2.3 months in control 
group patients. The median duration of response was 28.6 months (carfilzo-
mib group) compared to 21.2 months (control group). The clinical benefit rate 
was 90.9% (95% CI 87.6–93.6) in patients of the carfilzomib group versus 
76.3% (95% CI 71.8–80.4) in patients of the control group (p<0.001). 
The median time to progression was 31.4 months (carfilzomib group) com-
pared to 19.4 months (control group), resulting in a HR of 0.62 (95% CI 0.50–
0.76). The median time to next treatment was 17.3 months in the carfilzomib 
group and 12.1 months in the control group.  
365 of 396 patients (carfilzomib group) and 348 of 396 patients (control group) 
had at least one assessment for health-related quality of life at cycles 1, 3, 6, 
12 and 18. Compared to the control group, the patients’ health-related quali-
ty of life was improved in the carfilzomib group (during 18 cycles of treat-
ment), the p value for overall treatment effect was p < 0.001. The minimal 
clinically important difference for between-group differences on the QLQ-C30 
Global Health Status and Quality of Life scale (5.0 points) was met at cycle 
12 and approached at cycle 18. 
In the carfilzomib group, the median duration of treatment was 88.0 weeks 
(ranging from 1.0 to 185.0 weeks) compared to 57.0 weeks (ranging from 1.0 
to 201.0) in the control group. 
Adverse events (AEs) of grade 3 or higher occurred in 83.7% of carfilzomib-
group patients and in 80.7% of control-group patients. Serious AEs were re-
ported by 59.7% (carfilzomib group) and 53.7% (control group) of patients, 
they occurred most commonly during cycles 1–6 in the carfilzomib group 
and in cycles > 18 in the control group. AEs of specific interest of grade 3 or 
higher were dyspnoea (2.8% in the carfilzomib group vs. 1.8% in the control 
group), cardiac failure (in 3.8% of carfilzomib-group patients and 1.8% of 
control-group patients), ischaemic heart disease (3.3% of patients in the car-
filzomib group and 2.1% of patients in the control group), hypertension (4.3% 
in the carfilzomib group vs. 1.8% in the control group) and acute renal fail-
ure (3.3% in carfilzomib-group patients and 3.1% in control-group patients).  
previous regimens: 
bortezomib or 
lenalidomide 
median PFS 
significantly improved 
in carfilzomib group 
 
median OS not 
reached in either 
group 
ORR was 87.1% 
(carfilzomib group) vs. 
66.7% (control group) 
median time to 
progression was 
prolonged in  
carfilzomib group 
health-related quality 
of life was improved in 
the carfilzomib group 
AEs of grade 3 or 
higher in 83.7% 
(carfilzomib group) 
and 80.7% (control 
group) 
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The most common non-haematologic AEs of grade 3 or higher were fatigue 
(7.7% vs. 6.4% in carfilzomib group and control group respectively) and hypo-
kalaemia, which was reported by 9.4% of carfilzomib-group patients and 4.9% 
of control-group patients. In terms of haematologic AEs of grade 3 or higher, 
neutropenia occurred most commonly (29.6% in carfilzomib-group patients 
and 26.5% in control-group patients); anaemia and thrombocytopenia were 
reported by 17.9% and 16.6% of patients of the carfilzomib group compared 
to 17.2% and 12.3% of control-group patients. 
In total, 69.9% of patients in the carfilzomib group and 77.9% of control-
group patients discontinued treatment, most commonly due to disease pro-
gression (39.8% in carfilzomib-group patients and 50.1% in control-group pa-
tients) and the occurrence of AEs (15.3% in carfilzomib-group patients and 
17.7% in control-group patients). 12.5% of carfilzomib-group patients and 
6.9% of control-group patients discontinued treatment due to other reasons 
(e.g. multiple AEs). Due to AEs, the dose of carfilzomib was reduced in 11.0% 
of patients; the lenalidomide dose was reduced in 43.3% of carfilzomib-group 
patients and in 39.1% of control-group patients. 
7.7% of patients in the carfilzomib group and 8.5% of control-group patients 
died during treatment or within 30 days after they received the last dose of the 
study treatment. Deaths due to AEs occurred in 6.9% of patients in each treat-
ment group. Treatment-related deaths were reported in 14 patients (6 in the 
carfilzomib group and 8 in the control group); AEs leading to more than 2 
deaths in either group were myocardial infarction, cardiac failure and sepsis. 
 
 
6.2 Efficacy and safety – further studies 
PX-171-006 was a multicentre, single-arm, open-label phase Ib/II study of car-
filzomib, lenalidomide and low-dose dexamethasone in relapsed or progres-
sive multiple myeloma. The aim of the Ib part of the study [22] was to assess 
safety and to determine the maximum tolerated dose. The phase II part of 
the dose-expansion study [23] evaluated safety, secondary efficacy endpoints 
(ORR, PFS, duration of response) and exploratory endpoints (clinical benefit 
response rate and time to response). In total, 84 patients were included, 52 of 
whom received the maximum planned dose identified in the phase Ib study. 
The median age of these 52 patients was 63.0 years and they had received a 
median of 3 lines of prior therapies. 80.8% had been treated with bortezomib 
and 73.1% with lenalidomide. Treatment consisted of carfilzomib IV as a 2–
10-minute infusion on days 1, 2, 8, 9, 15 and 16 in 28-day cycles, starting with 
an initial carfilzomib dose of 20 mg/m
2
 on days 1 and 2 of the cycle, followed 
by a dosage of 27 mg/m
2
. Lenalidomide was administered orally at a dose of 
25 mg/day on days 1 to 21, and the patients received dexamethasone at 40 mg 
once weekly. ORR was 76.9%, median PFS was 15.4 months after a median 
follow-up of 24.4 months and duration of response was 22.1 months. The clin-
ical benefit rate was 76.9 and the patients’ median time to response was 0.95 
months. Treatment-emergent AEs occurred in all patients, a grade-3 or 4 event 
in 94.2% and a serious AE in 53.8% of patients respectively. The most com-
mon haematologic treatment-emergent AEs of grade 3 or 4 that occurred 
were lymphopenia (48.1%) and neutropenia (32.7%) followed by anaemia and 
thrombocytopenia; the most common non-haematologic treatment-emergent 
study treatment 
discontinuation in 
69.9% (carfilzomib 
group) and  
77.9% (control group) 
of patients 
treatment-related 
deaths in 6.9% of 
patients in each group 
phase Ib/II study 
evaluating carfilzomib, 
lenalidomide and 
dexamethasone 
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AEs of grade 3 or 4 were hypophosphataemia (25.0%) and fatigue (11.5%). 
Peripheral neuropathy grade 3 or 4 was observed in 1.9%.  
The FDA’s initial (accelerated) approval of single-agent carfilzomib for the 
treatment of patients with multiple myeloma who have received at least two 
prior therapies including bortezomib and an immunomodulatory agent was 
based on an open-label, single-arm phase II study [24]. A total of 266 patients 
of this study (PX-171-003-A1) [25] received single-agent carfilzomib at a dose 
of 20 mg/m
2
 IV twice weekly for 3 or 4 weeks in cycle 1, followed by 27 mg/m
2 
for ≤ 12 cycles. All patients (median age of 63 years) previously received an-
ti-myeloma therapy; 95% of patients were refractory to their last therapy, 80% 
were refractory or intolerant to both bortezomib and lenalidomide. The pa-
tients received a median of 5 (ranging from 1 to 20) prior lines of therapy, in-
cluding bortezomib (99.6% of patients), lenalidomide (94% of patients) and 
thalidomide (75% of patients). Furthermore, patients had previously received 
corticosteroids, alkylating agents and anthracycline; 74% of patients had a 
stem cell transplant. ORR (the primary endpoint of the study) was 23.7%; 
median DOR was 7.8 months. Median OS was 15.6 months, and the median 
PFS achieved was 3.7 months. The clinical benefit response rate was 37.0%. 
The most common AEs of grade 3 or 4 were thrombocytopenia (29% of pa-
tients), anaemia (24% of patients) and lymphopenia (20% of patients). The 
most frequent carfilzomib-related AEs of all grades were fatigue (37% of pa-
tients), nausea (34% of patients) and thrombocytopenia (29% of patients). The 
most common AEs associated with treatment discontinuation were hypercal-
caemia (associated with progressive disease), congestive heart failure, cardiac 
arrest, dyspnoea, pneumonia, spinal cord compression and increased serum 
creatinine. 11 patients (4.1%) died due to an AE.  
Safety data for the FDA approval of carfilzomib were evaluated in 526 patients 
with relapsed multiple myeloma who received carfilzomib as monotherapy 
[15]. 
Jakubowiak et al. [26] prospectively evaluated the impact of cytogenetic ab-
normalities on outcomes during the PX-171-003-A1 trial. In this multicenter, 
open-label, single-arm, phase 2 study, single-agent carfilzomib was adminis-
tered intravenously over 2–10 minutes on days 1, 2, 8, 9, 15 and 16 of each 
28-day cycle. The cytogenetic status was available in 229 patients; 72.9% had 
standard-risk cytogenetics and 27.1% were high-risk patients. The ORR was 
25.8% in the high-risk subgroup and 24.6% in the standard-risk subgroup; the 
clinical benefit rate was 30.7% in the high-risk group and 40.7% standard-risk 
subgroup. The incidence of progressive disease was 22.6% in the high-risk 
subgroup compared to 27.5% in the standard-risk subgroup. Due to progres-
sive disease within the first 2 cycles, 29.0% (high-risk subgroup) and 20.4% 
(standard-risk subgroup) of patients discontinued study treatment. Median 
OS was 9.3 months (high-risk subgroup) versus 19.0 months (standard-risk 
subgroup); median PFS was 3.5 months in the high-risk subgroup versus 4.6 
months in the standard-risk subgroup. 
PX-171-003-A0, an open-label, single-arm, multicentre, pilot phase II study 
[27] evaluated single-agent carfilzomib in 46 patients with relapsed and re-
fractory multiple myeloma after ≥ 2 prior therapies including bortezomib 
and an immunomodulator. Carfilzomib was administered IV at a dosage of 
20 mg/m
2
 on days 1, 2, 8, 9, 15 and 16 every 28 days for up to 12 cycles; addi-
tionally, dexamethasone (4 mg orally or IV) pre-medication was given. Due 
to results of the PX-171-002 study [28] that became available while this study 
was ongoing, the carfilzomib dose was escalated to 27 mg/m
2
 in 3 patients 
FDA approval based  
on a phase II study  
(PX-171-003-A1) 
including 266 patients 
 
 
assessing single-agent 
carfilzomib in 
pretreated patients  
impact of cytogenetic 
abnormalities 
evaluated in patients 
of  
PX-171-003-A1 trial 
pilot phase II study of 
single-agent 
carfilzomib in 46 
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(starting at cycles 8, 9 and 10, respectively). The ORR, the primary endpoint, 
was 16.7%, the clinical benefit response rate was 23.8%. The median dura-
tion of response achieved was 7.2 months (for the ORR population) and 13.8 
months (for patients achieving minimal response or better); the estimated me-
dian time to progression was 3.5 months and median PFS was 3.5 months; 
76.2% of patients had progressive disease or died. The most common haema-
tologic AEs of grade 3 or 4 were anaemia (37.0% of patients), lymphopenia 
(28.3% of patients) and thrombocytopenia (26.1% of patients). Other frequent 
AEs of grade 3 or 4 occurring were hyponatraemia (13.0% of patients) and 
renal/acute renal failure in 13.0% of patients. Peripheral neuropathy was seen 
in 15.2% of patients with all but one case being grade 1 or 2. 
Lendvai et al. [29] conducted a single-arm, single-centre, open-label phase II 
study in 44 patients with relapsed multiple myeloma. They received carfilzo-
mib as a 30-minute IV infusion on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. 
On days 1 and 2 of cycle 1, carfilzomib was administered at a dose of 20 mg/m
2
, 
followed by a dose escalation to 56 mg/m
2
 if tolerated. Low-dose dexametha-
sone (20 mg/m
2
) could have been added to restore anti-myeloma activity and 
to prolong treatment in patients whose disease progressed after achieving at 
least a partial response after 2 cycles and in patients who had not achieved at 
least a partial response after 2 cycles. The study population (median age of 
63 years) was heavily pretreated with a median of 5 (ranging from 1 to 11) 
prior lines of therapy; all patients had received prior bortezomib and an im-
munomodulatory agent (thalidomide/lenalidomide). 72% of the patients had 
had prior autologous stem cell transplantation and 22% had prior allogeneic 
stem cell transplantation. 77% of patients were refractory to bortezomib and 
64% of patients were refractory to both bortezomib and lenalidomide. ORR 
was 55% of which 31% of patients achieved at least a partial response. The 
median PFS was 4.1 months, the median OS was 20.3 months (after a medi-
an follow-up of 18.4 months). The most frequent treatment-emergent non-
haematologic AEs of any grade occurring in ≥ 20% of patients were diarrhoea, 
nausea, fatigue, headache and constipation. The most common carfilzomib-
related, treatment-emergent non-haematologic AEs of any grade occurring in 
≥ 20% of patients were fatigue, nausea, headache and upper respiratory in-
fection. The most frequent treatment-emergent AEs of grade 3 or 4 occurring 
in ≥ 5% of patients were lymphopenia (50%), leukopenia (43%), thrombocy-
topenia (39%) and anaemia (36%); the most common non-haematologic treat-
ment-emergent AEs of grade 3 or 4 were hypertension (25%), heart failure 
(20%), and pneumonia (18%).  
An open-label, single-arm phase II study [30] evaluated single-agent carfil-
zomib in patients with relapsed and/or refractory multiple myeloma. A total 
of 35 patients (median age of 63 years), all previously treated with bortezo-
mib, were enrolled. The median number of prior therapies was 3.0; 97.1% re-
ceived prior corticosteroid therapy, other commonly used drugs were alkyl-
ating agents (88.6% of patients), thalidomide (68.8% of patients) and lena-
lidomide (37.1% of patients). 77.1% of patients received prior therapy with 
thalidomide or lenalidomide. 20% of patients were refractory to bortezomib, 
62.9% were refractory to their last therapy regardless of the administered 
drug. The patients received carfilzomib IV at a dose of 20 mg/m
2
 over 2 to 10 
minutes on days 1, 2, 8, 9, 15 and 16 of every 28-day cycle for up to 12 cycles; 
prophylactic dexamethasone (4 mg/day) was given prior to each dose of car-
filzomib during the first cycle. 17.1% of patients achieved an ORR of 31.4% 
and a clinical benefit response rate. The median duration of response was 
> 10.6 months, the median time to progression was 4.6 months. The most 
phase II study of 
carfilzomib with/ 
without low-dose 
dexamethasone 
phase II trial of  
single-agent 
carfilzomib in patients 
pretreated with 
bortezomib 
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common non-haematological AEs of all grades were fatigue (62%), nausea 
(60%) and vomiting (42.9%); the most common haematological AEs of all 
grades were anaemia (34.3%), thrombocytopenia (31.4%) and neutropenia 
(25.7%). Most frequently occurring haematological AEs of grade 3 or higher 
were thrombocytopenia (20%), anaemia (14.3%) and neutropenia (11.4). The 
most common non-haematological AEs of grade 3 or higher were pneumonia 
(8.6%), dyspnoea, upper respiratory infection, hypertension, hypercalcaemia 
and epiglottitis (each 5.7%).  
Pharmacokinetics and safety of carfilzomib in multiple myeloma patients with 
renal impairment was assessed in an open-label, multicentre phase II study 
[31]. A total of 50 patients (median age of 64 years) with varying degrees of 
renal impairment and a median of 5 prior therapies (including corticosteroids, 
bortezomib, lenalidomide, thalidomide, alkylating agents, SCT and anthra-
cyclines) were included. 66% of patients were refractory to prior bortezomib 
therapy. 46% of patients were refractory to both bortezomib and lenalidomide. 
According to creatinine clearance, they were assigned to 5 groups: > 80 ml/ 
min, 50–80 ml/min, 30–49 ml/min, < 30 ml/min and chronic haemodialysis. 
The patients received a median number of 5 prior therapies and a median of 
4 cycles of carfilzomib. Carfilzomib was administered at a dose of 15 mg/m
2
 
in cycle 1; if tolerated, the dose was increased to 20 mg/m
2
 at cycle 2 and to 
27 mg/m
2
 at cycle 3 and in subsequent cycles. Dexamethasone was adminis-
tered prophylactically (4 mg); additionally, to improve response, patients with 
less than partial response after cycle 2 or less than complete response after 
cycle 4 were eligible to receive dexamethasone at a dose of 20 mg prior to 
each dose of carfilzomib. Analyses showed no differences in carfilzomib clear-
ance or exposure in patients, neither in patients with normal renal function 
nor in patients with renal impairment. The most common AEs of all grades 
(occurring in ≥25% of patients) were fatigue (56%) anaemia (50%), diarrhoea 
and nausea (each 36%). The most frequent haematologic AEs of grade 3 or 4 
occurring in ≥ 5% of patients were anaemia (28%), thrombocytopenia (20%) 
and lymphopenia (18%). Fatigue (14%), pneumonia (12%) and pain (10%) 
were the most common non-haematologic AEs of grade 3 or 4 occurring in 
≥ 5% of patients. 
Berdeja et al. [32] assessed the combination of panobinostat and carfilzomib 
in patients with relapsed/refractory multiple myeloma in 44 patients who had 
relapsed after at least one prior treatment. The study was conducted as a 
phase I/II, single-arm, open-label multicentre trial. The patients had a me-
dian age of 66 years and received a median of 5 prior therapies including 
bortezomib (89%), immune-modulating drugs (89%) and SCT (52%). 36% 
of patients were refractory to proteasome inhibitors, 30% were refractory to 
immune-modulating drugs, 14% were refractory to both bortezomib and im-
mune-modulating drugs and 43% were refractory to their last treatment. The 
patients received panobinostat on days 1, 3, 5, 15, 17 and 19, the established 
expansion dose was 30 mg. Carfilzomib was given on days 1, 2, 8, 9, 15 and 
16 of each 28-day cycle, the expansion dose was established at 20/45 mg/m
2
. 
Treatment was continued until progression or intolerable toxicity. The re-
sults showed an ORR of 67% for all patients; 67% for patients refractory to 
prior proteasome inhibitor treatment and 75% for patients refractory to pri-
or immune-modulating drug treatment. Median PFS was 7.7 months; medi-
an time to progression was also 7.7 months. Median OS had not been reached 
at a median follow-up of 17 months. The most common treatment-related 
toxicities of grade 3 or 4 were thrombocytopenia (38% of patients), neutro-
phase II study of 
carfilzomib in patients 
with renal impairment 
combination of 
panobinostat and 
carfilzomib 
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penia (21% of patients) and fatigue (11% of patients). One treatment-related 
death (2%) was reported. 
 
7 Estimated costs 
There is currently no cost information available regarding carfilzomib (Ky-
prolis
®
) for Austria.  
According to data from Germany, one vial of carfilzomib at 60 mg (obtained 
via International Pharmacy) costs € 1,432.76 [13] which is the same like in 
the US [1]. Assuming an average body surface of 1.8 m
2
 and a dosage of 20 
mg/m
2
 on days 1 and 2 and a dosage of 27 mg/m
2
 on days 8, 9, 15 and 16, pa-
tients receive a total dose of 266 mg of carfilzomib in the first cycle. In cycles 
2 to 12, a total dose of 292 mg of carfilzomib (6 infusions at 27 mg/m
2
) is ad-
ministered per cycle. Thus, for cycles 1 to 12, 5 vials of carfilzomib are need-
ed per cycle if any left-overs can be re-used, resulting in costs of € 7,163.8 
per cycle or in € 8,596.6 if new vials have to be used for each administration. 
In cycles 13 to 18, 4 doses of carfilzomib (at 27 mg/m
2
 on days 1, 2, 15 and 
16) are given in each cycle, resulting in costs of € 5,731.04 per cycle. In total, 
for 18 cycles of carfilzomib treatment, costs of € 120,351.84 would incur. Ad-
ditionally, costs for lenalidomide, dexamethasone, and antiviral and anti-
thrombotic prophylaxis incur. This cost estimation is based on the dosage 
scheme of the ASPIRE trial [21]. 
 
 
 
8 Ongoing research 
In June 2015, a search in two databases (www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu) was conducted and the following trials  
were identified: 
 NCT01568866 (EudraCT number 2012-000128-16): ENDEAVOR is a 
phase III, randomised open-label trial, comparing carfilzomib plus dex-
amethasone with bortezomib plus dexamethasone in patients with re-
lapsed multiple myeloma. The estimated study completion date is 
March 2019; the estimated primary completion date is January 2016. 
 NCT01302392 (EudraCT number 2009-016840-38): This open-label, 
randomised phase III trial (FOCUS) evaluates the efficacy of carfilzo-
mib versus best supportive care in patients with relapsed and refrac-
tory multiple myeloma who have received all available approved treat-
ment options and would otherwise be offered palliative care. The es-
timated study completion date is December 2015. 
 NCT02412878: ARROW, an open-label, randomised phase III study in 
patients with relapsed and refractory multiple myeloma receiving car-
filzomib plus dexamethasone compares one-weekly versus twice-week-
ly carfilzomib dosing. Estimated study completion date is September 
2018. 
no cost information 
available for Austria  
 
costs for 1 cycle:  
€ 5,731– € 7,164 
(depending on the 
number of infusions  
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Numerous phase II studies evaluate the use of carfilzomib in multiple mye-
loma in different dosages (e.g. weekly carfilzomib dose of 70 mg/m
2
 in patients 
who are refractory to 27 mg/m
2
) or in various combination regimens, includ-
ing combinations with bendamustine, panobinostat, vorinostat, pegylated lip-
osomal doxorubicin, pomalidomide, ibrutinib or selinexor. Furthermore, stud-
ies assess carfilzomib in different patient populations, such as younger trans-
plantation-eligible patients or elderly, symptomatic patients. There is also a 
large number of ongoing phase II trials, assessing carfilzomib in other malig-
nancies, e.g. mantle-cell lymphoma, neuroendocrine cancer, renal cell cancer, 
prostate cancer). 
 
 
 
9 Commentary 
In the US, carfilzomib (Kyprolis
®
) is indicated in combination with lenalid-
omide and dexamethasone for the treatment of patients with relapsed mul-
tiple myeloma who have received one to three prior lines of therapy and as a 
single agent for the treatment of patients with multiple myeloma who have 
received at least two prior therapies [8]. In Europe, the EMA granted orphan 
designation for carfilzomib for the treatment of multiple myeloma in 2008 
[9] but marketing authorisation is still outstanding.  
The FDA´s initial (accelerated) approval was based [15] on the results of a 
single-arm, open-label phase II study [25], evaluating the efficacy and safety 
of single-agent carfilzomib in 266 patients. Additionally, safety data were eval-
uated in 526 patients with relapsed multiple myeloma who had received car-
filzomib as monotherapy. Moreover, and as a condition for accelerated ap-
proval in 2012, the manufacturer had to submit the complete analysis of the 
ASPIRE trial [15]. 
This phase III trial was conducted in 792 patients with relapsed multiple mye-
loma who had received 1 to 3 prior lines of therapy [21]. Interim analyses 
showed a median PFS of 26.2 months for patients receiving carfilzomib in 
combination with lenalidomide and dexamethasone, resulting in a gain of 8.7 
months compared to patients treated with lenalidomide and dexamethasone 
only; risk reduction for PFS was 31%. The ORR was improved in the carfil-
zomib group (87.1%) compared to the control group (66.7%). Patients of the 
carfilzomib group achieved higher rates for complete response or better 
(31.8% vs. 9.3%) and for very good partial response or better (69.9% vs. 
40.4%). Median OS was not yet reached in either group at the time of inter-
im analysis; the Kaplan-Meier 24-month OS rates were 73.3% in the carfil-
zomib group versus 65.0% in the control group. In the carfilzomib group, 
health-related quality of life measured with the QLQ-C30 Global Health 
Status and Quality of Life scale showed a clinically important difference at 
12 weeks in comparison to the control group. 
AEs of grade 3 or higher were reported from 83.7% of carfilzomib-group pa-
tients and 80.7% of control-group patients; serious AEs were reported from 
59.7% (carfilzomib group) and 53.7% (control group) of patients; they oc-
curred most commonly during cycles 1 to 6 in the carfilzomib group and in 
cycles > 18 in the control group. 7.7% of patients of the carfilzomib group 
numerous  
phase II trials 
approved by the FDA, 
but not by the EMA 
PFS significantly 
improved in 
carfilzomib group 
 
ORR and health-
related quality of life 
were improved in 
carfilzomib group 
serious AEs in 59.7% 
(carfilzomib group) 
and 53.7% (control 
group) of patients 
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and 8.5% of the control group died during treatment or within 30 days after 
they received the last dose of study treatment [21].  
Safety data were also evaluated in a study summarising the results of 526 pa-
tients participating in 4 phase II trials of single-agent carfilzomib [33]. In 
terms of AEs of specific interest for multiple myeloma, including neuropathy, 
cardial and renal AEs, the authors reported the following: peripheral neuro-
pathy occurred in 7% of patients. A cardiac disorder AE of any kind occured 
in 22.1% of patients. In terms of renal AEs, 33.1% of patients had at least 
one grouped renal impairment AE including increased blood creatinine, acute 
renal failure, increased blood urea and decreased renal creatinine clearance 
[33]. 
Although the results of the ASPIRE trial concerning PFS, ORR and to some 
extent patients’ quality of life show improvements for these outcomes, further 
data are needed to better characterise the role of carfilzomib in the treatment 
of multiple myeloma, since several questions remain unanswered: 
 Carfilzomib versus bortezomib: The superior results of the ASPIRE 
study were obtained by add-on of carfilzomib to lenalidomide and dex-
amethasone in comparison to lenalidomide and dexamethasone. How-
ever, the comparison to bortezomib, also a proteasome inhibitor, is of 
high interest. Bortezomib is a reversible inhibitor, whereas carfil-
zomib is a covalent inhibitor. In vitro, carfilzomib showed greater se-
lectivity and less off-target activity than bortezomib and was active in 
cell lines that are resistant to bortezomib [34]. Moreover, the occur-
rence of peripheral neuropathy, an adverse effect limiting the use of 
bortezomib, seems to be reduced with carfilzomib administration [35, 
36]. However, treatment costs for bortezomib are lower.  
The results of the ENDEAVOR study (NCT01568866; currently on-
ly published only as abstract [37]) comparing carfilzomib with dex-
amethasone to bortezomib with dexamethasone might help to clarify 
this question; however, the maximum dose of carfilzomib was escalat-
ed to 56 mg/m
2
 in this trial and is therefore considerable higher than 
that used in the ASPIRE study.  
 Role of carfilzomib: Generally, the role of carfilzomib in multiple 
myeloma treatment, considering line of treatment and combination 
with other agents needs to be determined. On the one hand, it is cur-
rently in phase III for the treatment of newly diagnosed multiple my-
eloma. On the other hand and as mentioned above, some bortezomib-
resistant cell-lines respond to carfilzomib treatment [4, 34]. Even 
though carfilzomib was licensed for heavily pretreated patients based 
on phase II study results in the US [25], comparative data for patients 
non-responding/refractory to other available treatment options is 
scarce. In the ASPIRE trial, only 6% of patients were non-
responsive/refractory to bortezomib and an immunomodulatory 
agent and 15% did not respond to bortezomib. Further data from the  
FOCUS trial (scheduled until December 2015) comparing single 
agent carfilzomib with best supportive care in patients who have re-
ceived all available approved treatment options will help to clarify 
that question.  
Also, since carfilzomib is currently being studied as single agent but 
also in combination with other agents such as ibrutinib, benda-
mustine or panobinostat, a pan-deacetylase inhibitor, the best combi-
nation regimen, needs to be determined.  
open questions 
carfilzomib vs. 
bortezomib 
role of carfilzomib 
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 Influence of cytogenetic status: Since the cytogenetic status of patients 
is evaluated after multiple myeloma has been diagnosed [3], the im-
pact of cytogenetic abnormalities needs to be assessed. Even though 
subgroup analyses of the ASPIRE trial indicated that no difference 
exists between patients with high risk and standard risk cytogenetic 
profile and phase II study results support this finding [26, 29], only 
53% of patients had been tested for cytogenetic mutations. Overall, 
100 patients (13%) had a high cytogenetic risk at study entry and cy-
togenetic risk was unknown in 47% of patients in the ASPIRE study 
[21].  
 Role of novel agents for anti-myeloma therapy: The role of other pro-
teasome inhibitors and monoclonal antibodies in development for the 
treatment of multiple myeloma needs to be determined. Novel pro-
teasome inhibitors including ixazomib (MLN9708, a boronic acid) 
with reversible inhibiting mechanism, oprozomib (ONX-0912, an ex-
poxyketone) and marizomib (NPI0052, a salinosporide), which are ir-
reversible inhibitors, are currently under investigation [38].  
Since some of these new agents can be administered orally, the role of 
carfilzomib in comparison to these emerging proteasome inhibitors 
remains to be seen; although patients may strongly prefer oral options, 
their comparative efficacy and side-effect profiles are still under inves-
tigation [34]. The taxing administration scheme of carfilzomib re-
quiring patients to receive intravenous infusions on six days per 
month might limit the application of carfilzomib, especially when ef-
fective oral drugs are available. 
In terms of anti-CD38 monoclonal antibodies, particularly elotuzumab 
(anti-CS1) in combination with lenalidomide and dexamethasone has 
shown promising results [38]. Recently published results of a phase II 
study of single-agent daratumumab showed durable activity, deep re-
sponses and a favourable safety profile in patients with ≥ 3 lines of 
prior therapy and or double-refractory multiple myeloma [39].  
 Optimal dosage and schedule: The currently approved dosing for car-
filzomib is 20 mg/m
2
 initially, with a dose escalation, if tolerated to 
27 mg/m
2
 [11]. However, higher doses (up to 56 mg/m
2
) of carfilzomib 
were tolerable in phase I/II settings and are used in phase III trials 
[29]. Whether higher doses yield improved outcomes with manageable 
side-effects is still unknown. In any case, treatment costs would in-
crease further.  
 Applicability of study results: The ASPIRE trial study population had 
a median age of 64 years and more than 50% of them had already re-
ceived 2 or 3 previous treatment regimens [21]. Regarding that the me-
dian age at diagnosis of multiple myeloma is 69 years [6], the study 
population of the ASPIRE trial was considerably younger. Moreover, 
the majority (90.5%) of the study population had a good performance 
status of 0–1. These facts need to be considered concerning the applica-
bility of the study results. With regard to heavily pre-treated patients, 
the results of the FOCUS trial (NCT01302392), conducted in patients 
who had received at least 3 prior therapies, will be of interest.  
Patients with relapsed/refractory multiple myeloma are a heterogeneous pop-
ulation and several treatment options exist [40]. No standard treatment of 
patients with relapsed and/or refractory multiple myeloma exists and the ap-
propriate treatment depends on the disease status, the patient status or the 
drug components administered in initial therapy. For patients with multiple 
efficacy in high risk 
patients?  
novel agents can be 
administered orally 
optimal dosage and 
schedule 
applicability of  
study results 
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myeloma, the optimal combination regimens and timing of administration 
need to be determined; furthermore, patients need to be treated in future 
clinical trials [40]. Generally, combination regimens are preferred over mono-
therapy, and three-drug combination regimens are administered frequently. 
Although they might demonstrate superior efficacy regarding response rates, 
their effect on PFS and OS is not as clear [41]. 
Despite the promising results of the ASPIRE trial, further evidence is need-
ed to prove the efficacy (especially regarding overall survival) and safety of 
carfilzomib and to determine its role for the treatment of multiple myeloma. 
The most efficacious and safe combination with other drugs and the optimal 
line of treatment for carfilzomib administration needs to be assessed. More-
over, the patient population most suitable for carfilzomib treatment needs to 
be evaluated. Many issues have to be resolved, not least in light of the high 
cost of carfilzomib therapy.  
 
further evidence  
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